MRSA a leading culprit in thousands of hospital-acquired infections and deaths each year
ENGLEWOOD, Fla.–July 12, 2005 (PRIMEZONE)–SinoFresh HealthCare, Inc. (OTCBB:SFSH) today announced positive results of a controlled laboratory experiment studying the killing effectiveness of SinoFresh(tm) Nasal Spray against the deadly MRSA bacteria in vitro. Dr. Barry Kreiswirth, Ph.D., conducted the study at the Public Health Research Institute (PHRI) of Newark, NJ, where he is director of the Institute’s Tuberculosis Center and Hospital Infections Program.
The results showed 100% killing of an infectious concentration of MRSA virtually upon contact with SinoFresh(tm) Nasal Spray. Methicillin resistant Staphylococcus aureus derives its name from its resistance to commonly used antibiotics. It has become a major problem in hospitals and other extended care facilities where sick patients are particularly susceptible to infection.
William Wilferth, R.Ph., M.S., Vice President of R&D for SinoFresh HealthCare stated, “Through this and previous studies, we’ve now shown in vitro that SinoFresh(tm) eradicates representative strains of the three most common sources of upper respiratory illness — bacteria, viruses, and mold.” He continued, “We are very pleased that Dr. Kreiswirth, whose expertise in the characterization and surveillance of MRSA strains and infections has led to collaborations with the Centers for Disease Control and the National Institutes of Health, was able to provide his support and direction.”
The latest in vitro results will form part of the basis of discussion when SinoFresh HealthCare goes before the U.S. Food and Drug Administration (FDA) for a Pre-Investigational New Drug (Pre-IND) meeting to determine its course of action to gain drug status for a prescription version of SinoFresh(tm) Nasal Spray.
About SinoFresh HealthCare, Inc.
SinoFresh HealthCare, Inc. is a developer and marketer of innovative therapies for conditions of the upper respiratory system. The Company is researching broad-spectrum antiseptic approaches to reducing viral, bacterial, and fungal organisms that are suspected to cause pathogenesis of the mouth, nose, and throat. The Company holds many patents and patent applications on its innovative pharmaceutical technology and relies upon a distinguished panel of medical experts and a management team experienced in the bio-pharmaceutical arena.
The Company’s lead product, SinoFresh(tm) Nasal Spray, is a hygienic cleansing spray that kills germs and removes other nasal-sinus irritants. The Company is also researching how antiseptic cleansing may aid in alleviating sinus distress, a problem that may affect 37 million Americans annually. SinoFresh(tm) Nasal Spray Care is available nationwide in Wal-Mart, Walgreens, Rite Aid, CVS, Sav-on drugs, Osco Drug and other drug, grocery and mass merchandise retailers. More information is available at www.sinofresh.com
Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements speak only as of the date on which such statements are made and involve risks and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission, including risks summarized in the Company’s Annual Report on Form 10-KSB for its fiscal year ended December 31, 2004 (file No. 0-49764). The Company’s actual results could differ materially from such forward-looking statements. The Company undertakes no obligation to update any forward-looking statement or statements to reflect new events or circumstances or future developments.
SinoFresh(tm) is a trademark of SinoFresh HealthCare, Inc.
CONTACT: SinoFresh HealthCare, Inc.
Michael Gillette
(941) 681-3121
Investor Relations:
(941) 681-3135